Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Symbol: 002693.SZ
SHZ
5.69
CNYMarkedspris i dag
-39.5632
P/E-forhold
2.2749
PEG Ratio
2.36B
MRK Cap
- 0.00%
DIV Udbytte
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 31.9 | 146 | 77 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 28.5 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 16.4 | 41 | 33.1 | |||||||||||||||
balance-sheet.row.inventory | 0 | 74.3 | 65.4 | 55.2 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.2 | 0 | 0.1 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 135.2 | 252.4 | 165.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 457.6 | 471.8 | 504.7 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 10 | 8.8 | 17.3 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 1.5 | 1 | 1 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 27.1 | 12.2 | 9.1 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 668 | 658.6 | 689.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 17.1 | 15.5 | 17.2 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 10.1 | 205.3 | 0.3 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 3.7 | 12.8 | 7.2 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 135 | 0 | 167 | |||||||||||||||
Deferred Revenue Non Current | 0 | 8 | 7.6 | 8.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 73.6 | 1.8 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 145.7 | 10.7 | 179.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 285.6 | 330.1 | 287.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 34.4 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 416.7 | 414.7 | 412 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | -347 | -296.2 | -305.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -0.4 | 87.2 | 82.2 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 367.6 | 307.9 | 292.9 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 471.5 | 513.5 | 481.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 46.2 | 67.4 | 84.9 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 517.6 | 580.9 | 566.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 10 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 145.1 | 205.3 | 167.3 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 141.7 | 193.1 | 145.6 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 0 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | 0 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 0 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | 0 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | 0 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 0 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | 0 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | 0 | -7.8 | -8.1 | -62.1 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 235.9 | 274.8 | 320.3 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 74.9 | 88.3 | 81.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 161.1 | 186.5 | 238.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 183.4 | 215.8 | 282.7 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 258.3 | 304.1 | 364.1 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0.1 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 52.7 | 57.5 | 54.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | -73.2 | -24.5 | -42.3 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | -73 | -8.9 | -40.4 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1 | -0.4 | 0.4 | |||||||||||||||
income-statement-row.row.net-income | 0 | -50.7 | -8.5 | -40.8 |
Ofte stillede spørgsmål
Hvad er Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) samlede aktiver?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) samlede aktiver er 803248121.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er N/A.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.654.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -0.103.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -0.324.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -0.443.
Hvad er Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -50741578.370.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 145050750.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 183423820.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 0.000.